You are here

  • Home
  • Archive
  • Volume 6, Issue 2
  • Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial

Article info

Article menu
Protocol
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial

Authors

  • Yongjun Wang Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Claiborne Johnston The University of Texas at Austin Dell Medical School, Austin, Texas, USA PubMed articlesGoogle scholar articles
  • Philip M Bath Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, Nottinghamshire, UK PubMed articlesGoogle scholar articles
  • Xia Meng Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Jing Jing Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Xuewei Xie Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Anxin Wang Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Yuesong Pan Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Anding Xu Department of Neurology, The First Affiliated Hospital, Jinan University Guangzhou, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Qiang Dong Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yilong Wang Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Xingquan Zhao Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Zixiao Li Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Hao Li Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • For the CHANCE-2 Investigators
    Google scholar articles
  1. Correspondence to Dr Yongjun Wang; yongjunwang{at}ncrcnd.org.cn
View Full Text

Citation

Wang Y, Johnston C, Bath PM For the CHANCE-2 Investigators, et al
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial
Stroke and Vascular Neurology 2021;6:doi: 10.1136/svn-2020-000791

Publication history

  • Received December 9, 2020
  • Revised March 15, 2021
  • Accepted April 9, 2021
  • First published May 5, 2021.
Online issue publication 
June 29, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.